Xyphos, Parker Institute steer next-gen Car T therapies into solid tumors

Xyphos Biosciences Inc. (South San Francisco, Calif.) will partner with the Parker Institute for Cancer Immunotherapy to develop CAR Ts using Xyphos' convertibleCAR platform. Xyphos President

Read the full 266 word article

User Sign In